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Abstract
Purpose: The objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine 
regimen in patients with stage IIIB-IV non-small cell lung cancer (NSCLC).
Patients and Methods: Chemonaive patients with stage IIIB-IV NSCLC received either vinoelbine 30 mg/m
2 (days 1 and 8) 
plus cisplatin 80 mg/m
2 (day 1) every 21 days (VC arm) or gemcitabine 1250 mg/m
2 (days 1 and 8) plus cisplatin 80 mg/m
2 
(day 1) every 21 days (GC arm).
Results: One hundred thirtyfour patients (67 VC and 67 GC) were included to the study. Overall response rates for the VC 
arm (31.2%) were not signiﬁ  cantly different from that of the GC arm (34.3%). There were no differences in overall survival 
and one-year survival rates. Median survival and one-year survival rates for the VC and GC groups were 10.6 and 11.5 
months, 45% and 46.8%, respectively. Grade 3–4 thrombocytopenia was signiﬁ  cantly higher on the GC arm (VC 1.4% v 
Conclusion: VC and GC demonstrated similar efﬁ  cacy but there were differences in toxicity proﬁ  les.
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Introduction
Lung cancer is the leading cause of cancer deaths in both men and women. Appoximately one third of 
all cancer related deaths are due to lung cancer, which accounts for more deaths each year than breast, 
prostate, and colon cancer combined (Jemal et al. 2002).
Seventy-ﬁ  ve percent of patients with lung cancer present in inoperable, locally advanced (stage 
IIIB) or metastatic disease (stage IV) and are therefore candidates for some forms of systemic 
chemotherapy. Patients with advanced non-small cell lung cancer (NSCLC) have a poor outcome, 
with a survival time of approximately 4 to 6 months and 1-year survival rate of 10%–15% (Ginsberg 
et al. 1997).
Chemotherapy for advanced NSCLC was often considered ineffective or excessively toxic. However, 
meta-analyses have demonstrated that, as compared with supportive care, chemotherapy resulted in a 
small improvement in survival in patients with advanced NSCLC (Marino et al. 1994; Non-small Cell 
Lung Cancer Collaborative Group 1995; Grilli et al. 1993). In addition, randomized studies comparing 
chemotherapy with the best supportive care have shown that chemotherapy reduces symptoms and 
improves the quality of life .(Cullen et al.1999).
Over past decade, third generation agents such as vinorelbine, taxanes, gemcitabine and irinotecan 
have been introduced to the treatment of NSCLC. The combination of one or more of these agents with 
a platinum compound has resulted in high response rates and prolonged overall survival. However, 
there have been few comparisons of these newer chemotherapy regimens, which are now used frequently, 
with each other.
GC 8.9%, p   0.05), as was febrile neutropenia on the VC arm (VC 8.9% v GC 1.4%, p   0.05).28
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Therefore, we decided to investigate the activ-
ity and toxicity of two commonly used regimen s 
cisplatin and vinorelbine (VC) or cisplatin and 
gemcitabine (GC) in patients with stage IIIB or 
IVin this trial. The primary objective of this study 
was to compare overall survival.
Patients and Methods
We identiﬁ  ed consecutive patients with advanced 
stage NSCLC in our clinic. Data including demo-
graphic values, medical histories, symptoms and 
signs, laboratory examination results, and radio-
logic and scintigraphic documents were taken from 
ﬁ  les of the patients and archives of the department, 
respectively. Performance status was classiﬁ  ed in 
accordance with the criteria of European Coop-
erative Oncology Group (ECOG). Staging was 
conducted in accordance with WHO and TNM by 
evaluation of the imaging methods such as chest 
x-ray, thoracic computed tomography, abdominal 
computed tomography, abdominal ultrasonography 
(USG), cranial computed tomography and bone 
scintigraphy.
Eligibility criteria
The criteria for eligibility included conﬁ  rmed dis-
ease, measurable or nonmeasurable; an age of at 
least 18 years; adequate hematologic function (as 
indicated by a white-cell count of at least 4.000 
per cubic millimeter and a platelet count of at least 
100.000 per cubic millimeter), hepatic function (as 
indicated by a billirubin level that did not exceed 
1.5 mg per decilitre, and AST and ALT levels being 
less than three times of the normal values), and 
renal function (as indicated by a creatinine level 
that did not exceed 1.5 mg per deciliter); and 
ECOG performance status of  2.
Exclusion criteria
Criteria as to the exclusion from the study were 
as follows: insufficient hematological, renal 
and hepatic functions; instable brain metasta-
sis; history of prior chemotherapy and/or 
radiotherapy; presence of uncontrolled infections; 
presence of an additional malignancy; presence of 
a systemic disease contradicting administration 
of chemotherapy; pregnancy; performance status 
of  3; unﬁ  tness for follow-up due to psychological, 
familial, sociological and geographical reasons.
Treatment regimens
The main treatment was chemotherapy for 
patients with stage IV disease and sequential 
chemoradiotherapy for patients with stage IIIB 
disease.
Chemotherapy regimens
Cisplatin-plus-vinorelbine (VC) regimen
Vinorelbine, at a dose of 30 mg per square meter, 
was administered on days 1, and 8, and cisplatin, 
at a dose of 80 mg per square meter on day 1 of a 
three-week cycle. The cycle was repeated every 
three weeks.
Cisplatin-plus-gemcitabine (GC) regimen
Gemcitabine, at a dose of 1250 mg per square 
meter, was administered on days 1, and 8, and 
cisplatin, at a dose of 80 mg per square meter on 
day 1 of a three-week cycle. The cycle was repeated 
every 21 days.
At least two cycles were given to the patients 
were considered assessable for response. Patients 
who responded to the treatment and did not show 
signs of toxicity or progression were given four to 
six cycles. Dosage was adjusted according to 
hematological, neurological, renal and hepatic 
functions. Dosage was decreased by 25% for 
patients who were classiﬁ  ed as Grade III or Grade 
IV in accordance with WHO toxicity criteria.
Radiotherapy
Curative radiotherapy was administered for all 
patients with stage IIIB disease who had responded 
to chemotherapy after three cycles of chemother-
apy regimens. And remaining one to three cycles 
were given after three weeks to one-month after 
administration of radiotherapy. The doses of the 
thoracic radiotherapy was 60 Gy.
Outcome criteria
The aim of this nonrandomized comparison of 
retrospective study to evaluate the activity 
(response, overall survival) and toxicity of 
cisplatin-plus-vinorelbine and cisplatin-plus-
gemcitabine regimens in patients with stage IIIB-
IV non-small cell lung cancer. Standard ECOG 
response criteria were used. The response evalu-
ated by thorax CT scan at after three cycles of 29
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chemotherapy and end of the treatment. Brieﬂ  y, a 
complete response was deﬁ  ned as the absence of 
disease at all known sites for at least four weeks. 
A partial response was deﬁ  ned as a 50 percent 
reduction in the sum of the perpendicular diameters 
of all measurable lesions, lasting at least four 
weeks. Progressive disease was deﬁ  ned as either 
a 25 percent increase in the area of any one lesion 
over the prior measurement or the development of 
one or more new lesions. Survival was calculated 
from the date of diagnosis to the date of death or 
the date when the patient last known to be alive.
All patients gave written informed consent.
Statistical analysis
Data was evaluated by using SPSS 10.0 programme 
(SPSS Inc., Chicago, IL, U.S.A). Survival of the 
patients was calculated from the date of diagnosis 
to the date of death. Response rates were calculated 
for patients with complete or partial responses. 
Median age, smoking habits, performance status, 
response rates and toxicity results of the groups 
were compared by using “Mann-Whitney U” and 
“Pearson chi-square” tests. Median survival and 
one-year survival rates of the groups were calcu-
lated by Kaplan–Meier method (Kaplan et al. 
1958). Median survival rates were compared by 
using log-rank test. In all tests, p value was con-
sidered to be signiﬁ  cant when it was 0.05 or less.
Results
A total of 134 patients (67 patients for the VC group 
and 67 patients for the GC group) were enrolled in the 
study between January 2001 and September 2004.
The baseline characteristics of the patients in 
the two groups were similar (Table 1). The median 
age was 60.2 years. Almost 97 percent of the 
patients were men. Only 5.2 percent of the patients 
were non-smoker. 89.4 percent of patients had a 
performance-status score of 1, and 2. The median 
age was 58.9 years in VC and 61.6 years in GC 
group. About 71.6 percent of the patients had 
squamous carcinoma, and 64.9 percent had stage 
IIIB disease. There was no statistical difference 
between the groups with respect to baseline clinical 
characteristics of the patients. The median number 
of cycles was 3.5 for patients in VC group and 3.8 
for those in GC group.
Table 2 presents outcome results of the treatment 
groups. The overall response rate for the 134 
eligible patients was 32.7 percent. There were no 
significant differences in the response rate or 
survival among the groups. The response rates were 
31.2 percent for patients in VC group and 34.3 
percent for patients in GC group. The median 
survival was 10.6 months among the patients who 
received VC, 11.5 months among those who 
received GC. The one-year survival rate was 45 
percent for patients who received VC and 
46.8 percent for patients who received GC 
(Table 3 and Fig. 1).
The median survival was 11.2 months among 
the patients with stage III B disease treated with 
VC and 11.7 months among the patients with stage 
III B disease who received GC. For patients with 
stage IV disease the median survival was 9.7 
months, and 11.0 months, respectively.
All patients were evaluated for toxicity. Table 
III shows toxic effects of the treatment groups. No 
treatment-related death was observed and no patient 
was withdrawn from the study due to toxicity. The 
major hematological toxicities encountered in this 
study were neutropenia, febrile neutropenia, throm-
bocytopenia and anemia. Percentages of both grade 
3–4 anemia and grade 3−4 neutropenia were simi-
lar to each other in two groups. Febrile neutropenia 
was seen in 6 patients (8.9%) who received VC and 
in only 1 patient (1.4%) who received GC and this 
difference was statistically signiﬁ  cant (Pearson 
chi-square test, p = 0.02). Grade 3–4 thrombocyto-
penia occurred in 1 patient (1.2%) who received 
VC and in 6 patients (8.9%) who received GC, the 
difference was statistically signiﬁ  cant (Pearson 
chi-square test, p   0.05). No serious hemorrhagic 
events were noted on either regimens.
Non-hematological toxicity was minimal. Grade 
3–4 nausea and vomiting were observed only in 3 
patients (4.4%) in VC arm and in 2 patients (2.9%) 
in GC arm. And the difference was not statistically 
signiﬁ  cant.
Discussion
Platinum-based chemotherapy regimen for 
advanced stage non-small-cell lung cancer 
results in a small but statistically significant 
improvement in survival, as compared with best 
supportive care (Marino et al. 1994). Chemo-
therapy in non-small cell lung cancer: a meta-
analysis using updated data on individual patients 
from 52 randomised clinical trials (Non-small Cell 
Lung Cancer Collaborative Group, 1995; Grilli 
et al. 1993).30
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Although older chemotherapy regimens (e.g. 
mitomycin, ifosfamide, and cisplatin) resulted in 
survival rates of 10 to 15 percent at one year, sec-
ond-generation regimens (e.g. cisplatin and etopo-
side) have resulted in survival rates of 20 to 25 
percent at one year. The combination of the plati-
num analogues with the third generation drugs 
produce overall response rates of 30%–40%, 
median survival of 8 to 10 months, and 1-year 
survival rate of 30%–40% (Blackhall et al. 2004).
The evaluation of 10 randomized studies and 4 
meta-analyses showed that combined chemo-
therapies and platinum-based chemotherapies 
provided a 10% increase in 1-year survival rate 
with a median survival of up to 25 weeks. Our 
study showed that third-generation regimens result 
in survival rates of 45 to 46.8 percent at one year. 
(Cullen et al. 1999; Cartei et al. 1993; Cellerino 
et al. 1991; Cormier et al. 1982; Ganz et al.1989; 
The Elderly Lung Cancer Vinorelbine Italian Study 
Group, 1999; Kaasa et al. 1991; Quoix et al. 1991; 
Rapp et al. 1988; Woods et al. 1990; Marino et al. 
1994; Non-small Cell Lung Cancer Collaborative 
Group 1995; Grilli et al. 1993; Souquet et al. 
1993).
We sought to determine whether there was a 
difference in between two newer third-generation 
chemotherapy regimens, with respect to survival. 
There was no statistically signiﬁ  cant difference 
in survival between two regimens though patients 
in GC arm (11.5 months) had one month longer 
median survival than those in VC arm (10.6 months). 
Table 1. Baseline characteristics of the patients.
Characteristic Cisplatin and vinorelbine
(N = 67)
Cisplatin and gemcitabine
(N = 67)
Age (yr)
Median 58.9 61.6
Range 34–79 44–78
Sex (% of patients)
Female 4.5 1.49
Male 95.5 98.5
Smoking status (% of patients)
Nonsmoker 7.5 2.9
 10 pack/year 00
10–20 pack/year 7.5 8.9
21–30 pack/year 20.9 25.3
 30 pack/year 64.1 62.6
Performance status (% of patients)
0 5.9 5.9
1 47.7 47.7
2 46.2 46.2
Disease stage (% of patients)
IIIB 58.2 71.6
IV 41.8 28.3
Histological type (% of patients)
Squamous cell 64.1 79.1
Adenocarcinoma 19.5 13.4
Undifferentiated NSCLC 16.4 7.4
Metastasis sites (no. of patients)
13 2 2 0
27 6
 3 32
Brain metastasis (no. of patients) 12 7
*Mann-Whitney U test ,** Pearson chi-square test.
Abbreviations: CV: Cisplatin-Vinorelbine; CG: Cisplatin-Gemcitabine; NSCLC: Non-small cell lung carcinoma.31
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One-year survival rates were 45% and 46.8% for 
VC arm and GC arm, respectively (p   0.05). The 
overall response rate was 32.7 percent; the response 
rates were 31.2 percent for patients in VC group 
and 34.3 percent for patients in GC group. And 
there were no signiﬁ  cant differences in the response 
rates between two groups.
In a multicentre phase III study, 272 patients 
were randomised to receive either vinorelbine 25 
mg/m
2 on days 1 and 8 plus cisplatin 75 mg/m
2 on 
day 1 (regimen A) or gemcitabine 1200 mg/m
2 on 
days 1 and 8 plus cisplatin 75 mg/m
2 on day 1 
(regimen B) (Martoni et al. 2005). Both treatments 
were recycled every 21 days. The following 
response rates were observed in regimens A and 
B, respectively: complete response was 0.7% and 
3.7%, partial response was 31.9% and 22.2% 
(p = 0.321). Median overall survival was 11 months 
for both groups. Grade III-IV neutropenia occurred 
in 30.7% and 17.7% of the patients in arms A and 
B, respectively (p = 0.017); thrombocytopenia 
occurred in 0% and 9.3% (p = 0.004), respectively. 
Anemia rates were similar in both groups. A com-
parison of these data with ours showed that we had 
similar response rates with survival values despite 
the higher rate of complete response in our study. 
Table 2. Outcomes of treatment groups.
Variable Cisplatin and vinorelbine
(N = 67) 
Cisplatin and gemcitabine
(N = 67)
P
Response-%
Complete response 7.4 5.9
Partial response 23.8 28.4
Stable disease 49.2 35.8
Progressive disease 19.4 29.8
Overall response rate-% 31.2 34.3 0.71*
Survival
Median (95% CI)-mo 10.6 (8.7–12.5) 11.5 (10.0–13.0) 0.45**
One-year survival-% 45 46.8
*Pearson chi-square test.
**Log-rank test.
Abbreviations: CV: Cisplatin + Vinorelbine; CG: Cisplatin + Gemcitabine.
Table 3. Toxic effects.
Type of toxic effect Cisplatin and vinorelbine
(N = 67)
Cisplatin and gemcitabine
(N = 67)
% of patients
Anemia
Grade 1–2 46.2 41.7
Grade 3–4 8.9 7.4
Neutropenia
Grade 1–2 44.7 35.8
Grade 3–4 1.4 8.9
Febrile neutropenia 8.9* 1.4
Thrombocytopenia
Grade 1–2 5.9 11.9
Grade 3–4 1.4 8.9*
Nausea and vomiting
Grade 1–2 65.6 58.2
Grade 3–4 4.4 2.9
Pearson chi-square test.
*p   0.05.32
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However, the toxicity values were lower in our 
study except for thrombocytopenia in vinorelbine 
arm. Consequently, both studies showed no statis-
tically signiﬁ  cant superiority for VC or GC over 
each other.
A large, multicenter, randomised trial conducted 
by the Italian Cancer Project compared gemcitabine 
1250 mg/m
2 days 1 and 8 plus cisplatin 75 mg/m
2 
day 2 every 21 days (gemcitabine arm), or 
paclitaxel 225 mg/m
2 then carboplatin (area under 
the concentration-time curve of 6 mg/mLmin), both 
on day 1 every 21 days (PCb arm), or vinorelbine 
25 mg/m
2/wk for 12 weeks then every other week 
plus cisplatin 100 mg/m
2 day 1 every 28 days 
(vinorelbine arm) (Scagliotti et al. 2002). Overall 
response rates for the gemcitabine (30%) and PCb 
(32%) arms were not signiﬁ  cantly different from 
that of the vinorelbine arm (30%). There were no 
differences in overall survival, time to disease 
progression, or time to treatment failure. Median 
survival for the gemcitabine, PCb, and vinorelbine 
groups was 9.8, 9.9, and 9.5 months, respectively. 
Neutropenia (43%) was signiﬁ  cantly higher on the 
vinorelbine arm and thrombocytopenia (16%) 
on the gemcitabine arm. Their conclusion was 
that efﬁ  cacy end points were not signiﬁ  cantly 
different between arms, although toxicities showed 
differences. A comparison of these values to ours 
revealed that efﬁ  cacy and toxicity (especially neu-
tropenia) values of our study were better that may 
be due to (1) higher percentage of stage IIIB 
patients versus stage IV patients (58% vs 42% in 
vinorelbine arm, 71.6% vs 28.3% in gemcitabine 
arm) in our study than those of Italian Cancer 
Project (19% vs 81% in both gemcitabine and 
vinorelbine arms) and (2) weekly administration 
of vinorelbine in Italian Cancer Project rather than 
on days 1 and 8 every 21 days.
Since there are a few studies comparing VC 
with GC in advanced stage non-small-cell lung 
cancer, we also included results of studies that 
compared VC or GC with other regimens (Le 
Chevalier et al. 1994; Wozniak et al. 1998; Schiller 
et al. 2002; Abratt et al. 1997; Anton et al. 1998; 
Comella et al. 2000; Cappuzzo et al. 2000; 
Huisman et al. 2001; Kelly et al. 2001; Fossella 
et al. 2003). In these studies, a response rate of 
22%–54%, a median survival of 8.1–14.3 months 
and a one-year-survival rate of 33%–58% were 
reported for GC, response rate of 26%–57%; 
median survival of 7.1–11 months and one-year-
survival rate of 28%–41% were reported for VC.
Figure 1
Median survival: GC = 11.5 mo 
VC = 10.6 mo 
Logrank test: p > 0.05 
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Apparently, the ﬁ  ndings of our study are closer 
to the higher values in the literature. This may be due 
to the fact that in our study the number of stage IIIB 
patients is higher than that of the stage IV patients 
and that the number of patients who have two or 
more metastases is low. Another reason may be the 
regional differences but we were not able to compare 
our study with other studies due to lack of studies 
involving large series of patients in our country. The 
contrasts of results between our study and these 
studies may be related to differences at doses and 
schemes of cisplatin, vinorelbine and gemcitabine.
Toxicity results of our study showed that grade 
3–4 thrombocytopenia occurred in 1.4% and 8.9% 
of the patients in VC and GC, respectively 
(p   0.05); febrile neutropenia occurred in 8.9% 
and 1.2% (p   0.05), respectively. Grade 3–4 ane-
mia, grade 3–4 neutropenia and grade 3–4 nausea-
vomiting rates were similar in both groups. There 
is a wide variety in toxicity rates of previous stud-
ies that report grade 3–4 anemia as 7%–24% and 
20%–30% of the patients in VC and GC, respec-
tively; grade 3–4 neutropenia as 5.4-38.5% and 
13.8%–81%; grade 3–4 thrombocytopenia rates as 
2.5%–20% and 2.5%–6%; and grade 3–4 nausea-
vomiting as 0%–58% and 3.2%–39%, respectively 
(Comella et al. 2000; Kelly et al. 2001; Crino et al. 
1999; Cardenal et al. 1999). Our toxicity results 
were consistent with those of previous studies.
In conclusion, no signiﬁ  cant difference in survival 
was observed between VC and GC regimens, 
although patients in the latter regimen had one month 
longer survival. On the basis of toxicity results, grade 
3–4 thrombocytopenia and febrile neutropenia were 
signiﬁ  cantly higher in GC and VC, respectively.
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